logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to tackling Alzheimer's

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's potential use in the treatment of Alzheimer's Disease.

Tiziana is the exclusive owner of the world-wide rights for the nasal anti-CD3 for Alzheimer's, MS as well as a number of other neurological diseases .... ''this has a wide potential and it's all been licensed by Tiziana'', he says.

''We're going to look for fast-track designation or encouragement from the FDA because there are no treatments for Alzheimer's Disease ... so we're hoping the FDA will allow us to move this forward as quickly as possible.

''I presented to Tiziana the nasal delivery of Foralumab which they liked very much, we've been working on it, developing it, we actually now have carried on a Phase I trial in healthy volunteers - it's safe, we know the right doses so it's ready to move forward into clinical development.''

Quick facts: Tiziana Life Sciences PLC

Price: 114 GBX

AIM:TILS
Market: AIM
Market Cap: £189.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 lower as US infections continue to rise

Headlines from the Proactive UK newsroom. The FTSE 100 headed lower in an uncertain start to the week as investors worried over the surge in US COVID-19 infections. The blue-chip index dipped 24 to 6,135. Deliveroo’s boss has warned that restaurants are 'hurting' due to the coronavirus...

1 week, 4 days ago

2 min read